Revenue increased by 20% to $3.944 million in 2025 from $3.277 million in 2024. Gross profit increased by 38% to $2.358 million in 2025 from $1.711 million in 2024, with the gross profit percentage rising from 52% to 60%. Net loss decreased to $12.556 million in 2025 from $13.673 million in 2024. Operating expenses slightly decreased to $15.150 million in 2025 from $15.477 million in 2024. Acquired substantially all assets of SiVantage, Inc. and SIMPL Medical, LLC in August 2025, adding The SImmetry+ System to its product portfolio. Received a Nasdaq notice on February 25, 2026, for not maintaining a minimum closing bid price of $1.00, with a compliance period until August 24, 2026. Raised approximately $4.3 million in gross proceeds from a private placement of convertible promissory notes on March 11, 2026. The independent registered public accounting firm included an explanatory paragraph in its report on the financial statements for the fiscal year ended December 31, 2025, describing substantial doubt about the company's ability to continue as a going concern. The company had an accumulated deficit of $81.3 million as of December 31, 2025, and cash and cash equivalents of $3.8 million.